Latest news with #MartineRothblatt
Yahoo
7 days ago
- Health
- Yahoo
Leaders in Medicine and Science Celebrate Innovation at the Feinstein Institutes During Two Annual Academic Events
The Academy of Scholars Symposium and Elmezzi Graduate School Commencement celebrate and spotlight the importance of translational biomedical research MANHASSET, N.Y., June 03, 2025--(BUSINESS WIRE)--Top physician-scientists gathered on Long Island for a two-day celebration of medical research and achievement hosted by Northwell Health's Feinstein Institutes for Medical Research. On May 21, the Feinstein Academy of Scholars Symposium, an integrated network of researchers and scholars who share a passion for revolutionizing translational research, hosted its 8th annual symposium at the Oheka Castle, Huntington, NY. The next day, at the Feinstein Institutes in Manhasset, NY, the 2025 commencement ceremony of the Elmezzi Graduate School of Molecular Medicine took place, where two new PhDs were conferred along with two honorary degrees given to Akiko Iwasaki, PhD, Sterling Professor of Immunology at Yale University School of Medicine and Martine Rothblatt, PhD, JD, CEO of United Therapeutics Corporation. "The Feinstein Institutes' commitment to translational research was evident throughout this two-day celebration," said Bettie M. Steinberg, PhD, interim dean of the Elmezzi Graduate School of Molecular Medicine and professor in the Feinstein Institutes Institute of Molecular Medicine. "The symposium highlighted cutting-edge discoveries poised to move from the lab to the clinic, while the Elmezzi graduates represent the next generation of scientists dedicated to turning scientific advancements into tangible therapies." Meeting of minds at the Feinstein Academy of Scholars Symposium Members of the Academy include recipients of honorary doctoral degrees from the Elmezzi Graduate School of Molecular Medicine, Marsh and Match visiting lecturers, recipients of the Cerami, Ross and Advancing Women in Science and Medicine (AWSM) prizes, and researchers from the Feinstein Institutes. This year's featured keynote speakers included: Tobias Janowitz, MD, PhD, associate professor and Cancer Center Program Leader at Cold Spring Harbor Laboratory, provided an overview of the current research on systemic signaling in paraneoplasia, emphasizing the importance of this area of study. Lopa Mishra, MD, co-director and professor in the Institute of Bioelectronic Medicine at the Feinstein Institutes and Susan and Herman Merinoff Distinguished Chair in Translational Medicine, explained how specific environmental toxins contribute to liver cancer and outlined methods to selectively target these cancer cells. Akiko Iwasaki, PhD, Sterling Professor of Immunology at Yale University School of Medicine, spoke about examining the role of immune dysregulation in the pathogenesis of post-acute infection syndrome. Douglas F. Nixon, MD, PhD, Karches Family Professor in Translational Research and director and professor, Institute of Translational Research at the Feinstein Institutes, spoke about human endogenous retroviruses (HERVs) are part of our non-coding DNA and that our own genomes can impact our health and disease. Max Brenner, MD, PhD, associate professor in the Institute of Molecular Medicine at the Feinstein Institutes, spoke about an Elmezzi scholar's scientific journey stemming from the classroom to the clinic and the lab. Linda Van Aelst, PhD, professor at Cold Spring Harbor Laboratory, discussed the intricate involvement of Rho regulators in synapse formation and dysfunction. Celebrating the future of medical research On May 22, two clinicians were conferred their PhD during the Elmezzi Graduate School of Molecular Medicine graduation. This unique PhD program is for physicians (MDs) who wish to pursue careers in biomedical research. During the program, Elmezzi students conduct research in Feinstein Institutes laboratories to advance medical research and pursue new therapeutic approaches and diagnostic tools. The Elmezzi Graduate School of Molecular Medicine is supported in part by a generous endowment from the Thomas and Jeanne Elmezzi Foundation. Two honorary degrees were bestowed at the Elmezzi commencement. The first to Dr. Iwasaki for her research on immune defense against viruses at mucosal surfaces, and to Dr. Rothblatt for her contributions to new treatments for rare diseases and advances in organ transplants. In addition, she was the creator of the satellite radio company SiriusXM. This year's graduates include: Willians Tambo Ayol, MD, investigated the role of microvascular dysfunction in cognitive impairment and dementia, and explored the therapeutic potential of the diving reflex's protective mechanisms against cerebral hypoperfusion. Santhoshi Poonacha Palandira, MBBS, MS, MCh, applied optogenetics to neuromodulate brainstem nuclei to regulate inflammation. She also identified celiac-superior mesenteric ganglion complex in the abdomen and identified it as a new therapeutic target for noninvasive bioelectronic therapies to treat inflammation with a translational potential. "Physician-scientists produce the innovations and discoveries that make a healthier world," said Kevin J. Tracey, MD, president and CEO of Feinstein Institutes and Karches Family Distinguished Chair in Medical Research. "Elmezzi graduates are committed to career paths that will lead to new therapies and diagnostics." To find out more about the Elmezzi Graduate School of Molecular Medicine and its programs, click here. About The Elmezzi Graduate School of Molecular Medicine: The Elmezzi Graduate School of Molecular Medicine at Northwell Health offers MDs an accelerated PhD three-year program emphasizing translational research. Its mission is to provide academic training for physicians to discover and understand the causes of human diseases and to rapidly and effectively translate this information into diagnostic and therapeutic solutions. The program started in 1994 and is supported in part by a generous endowment from The Thomas and Jeanne Elmezzi Foundation. To date, more than 50 physician-scientists have graduated from the prestigious program. The Elmezzi School of Molecular Medicine is accredited by the WASC Senior College and University Commission (WSCUC). For more information, click here. About the Feinstein Institutes The Feinstein Institutes for Medical Research is the home of the research institutes of Northwell Health, the largest health care provider and private employer in New York State. Encompassing 50+ research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its six institutes of behavioral science, bioelectronic medicine, cancer, health system science, molecular medicine, and translational research. We are the global scientific leader in bioelectronic medicine – an innovative field of science that has the potential to revolutionize medicine. The Feinstein Institutes publishes two open-access, international peer-reviewed journals Molecular Medicine and Bioelectronic Medicine. Through the Elmezzi Graduate School of Molecular Medicine, we offer an accelerated PhD program. For more information about how we produce knowledge to cure disease, visit and follow us on LinkedIn. View source version on Contacts Julianne Mosher Allen516-880-4824jmosherallen@ Sign in to access your portfolio
Business Wire
7 days ago
- Health
- Business Wire
Leaders in Medicine and Science Celebrate Innovation at the Feinstein Institutes During Two Annual Academic Events
MANHASSET, N.Y.--(BUSINESS WIRE)--Top physician-scientists gathered on Long Island for a two-day celebration of medical research and achievement hosted by Northwell Health's Feinstein Institutes for Medical Research. On May 21, the Feinstein Academy of Scholars Symposium, an integrated network of researchers and scholars who share a passion for revolutionizing translational research, hosted its 8 th annual symposium at the Oheka Castle, Huntington, NY. The next day, at the Feinstein Institutes in Manhasset, NY, the 2025 commencement ceremony of the Elmezzi Graduate School of Molecular Medicine took place, where two new PhDs were conferred along with two honorary degrees given to Akiko Iwasaki, PhD, Sterling Professor of Immunology at Yale University School of Medicine and Martine Rothblatt, PhD, JD, CEO of United Therapeutics Corporation. 'The Feinstein Institutes' commitment to translational research was evident throughout this two-day celebration,' said Bettie M. Steinberg, PhD, interim dean of the Elmezzi Graduate School of Molecular Medicine and professor in the Feinstein Institutes Institute of Molecular Medicine. 'The symposium highlighted cutting-edge discoveries poised to move from the lab to the clinic, while the Elmezzi graduates represent the next generation of scientists dedicated to turning scientific advancements into tangible therapies.' Meeting of minds at the Feinstein Academy of Scholars Symposium Members of the Academy include recipients of honorary doctoral degrees from the Elmezzi Graduate School of Molecular Medicine, Marsh and Match visiting lecturers, recipients of the Cerami, Ross and Advancing Women in Science and Medicine (AWSM) prizes, and researchers from the Feinstein Institutes. This year's featured keynote speakers included: Tobias Janowitz, MD, PhD, associate professor and Cancer Center Program Leader at Cold Spring Harbor Laboratory, provided an overview of the current research on systemic signaling in paraneoplasia, emphasizing the importance of this area of study. Lopa Mishra, MD, co-director and professor in the Institute of Bioelectronic Medicine at the Feinstein Institutes and Susan and Herman Merinoff Distinguished Chair in Translational Medicine, explained how specific environmental toxins contribute to liver cancer and outlined methods to selectively target these cancer cells. Akiko Iwasaki, PhD, Sterling Professor of Immunology at Yale University School of Medicine, spoke about examining the role of immune dysregulation in the pathogenesis of post-acute infection syndrome. Douglas F. Nixon, MD, PhD, Karches Family Professor in Translational Research and director and professor, Institute of Translational Research at the Feinstein Institutes, spoke about human endogenous retroviruses (HERVs) are part of our non-coding DNA and that our own genomes can impact our health and disease. Max Brenner, MD, PhD, associate professor in the Institute of Molecular Medicine at the Feinstein Institutes, spoke about an Elmezzi scholar's scientific journey stemming from the classroom to the clinic and the lab. Linda Van Aelst, PhD, professor at Cold Spring Harbor Laboratory, discussed the intricate involvement of Rho regulators in synapse formation and dysfunction. Celebrating the future of medical research On May 22, two clinicians were conferred their PhD during the Elmezzi Graduate School of Molecular Medicine graduation. This unique PhD program is for physicians (MDs) who wish to pursue careers in biomedical research. During the program, Elmezzi students conduct research in Feinstein Institutes laboratories to advance medical research and pursue new therapeutic approaches and diagnostic tools. The Elmezzi Graduate School of Molecular Medicine is supported in part by a generous endowment from the Thomas and Jeanne Elmezzi Foundation. Two honorary degrees were bestowed at the Elmezzi commencement. The first to Dr. Iwasaki for her research on immune defense against viruses at mucosal surfaces, and to Dr. Rothblatt for her contributions to new treatments for rare diseases and advances in organ transplants. In addition, she was the creator of the satellite radio company SiriusXM. This year's graduates include: Willians Tambo Ayol, MD, investigated the role of microvascular dysfunction in cognitive impairment and dementia, and explored the therapeutic potential of the diving reflex's protective mechanisms against cerebral hypoperfusion. Santhoshi Poonacha Palandira, MBBS, MS, MCh, applied optogenetics to neuromodulate brainstem nuclei to regulate inflammation. She also identified celiac-superior mesenteric ganglion complex in the abdomen and identified it as a new therapeutic target for noninvasive bioelectronic therapies to treat inflammation with a translational potential. 'Physician-scientists produce the innovations and discoveries that make a healthier world,' said Kevin J. Tracey, MD, president and CEO of Feinstein Institutes and Karches Family Distinguished Chair in Medical Research. 'Elmezzi graduates are committed to career paths that will lead to new therapies and diagnostics.' To find out more about the Elmezzi Graduate School of Molecular Medicine and its programs, click here. About The Elmezzi Graduate School of Molecular Medicine: The Elmezzi Graduate School of Molecular Medicine at Northwell Health offers MDs an accelerated PhD three-year program emphasizing translational research. Its mission is to provide academic training for physicians to discover and understand the causes of human diseases and to rapidly and effectively translate this information into diagnostic and therapeutic solutions. The program started in 1994 and is supported in part by a generous endowment from The Thomas and Jeanne Elmezzi Foundation. To date, more than 50 physician-scientists have graduated from the prestigious program. The Elmezzi School of Molecular Medicine is accredited by the WASC Senior College and University Commission (WSCUC). For more information, click here. About the Feinstein Institutes The Feinstein Institutes for Medical Research is the home of the research institutes of Northwell Health, the largest health care provider and private employer in New York State. Encompassing 50+ research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its six institutes of behavioral science, bioelectronic medicine, cancer, health system science, molecular medicine, and translational research. We are the global scientific leader in bioelectronic medicine – an innovative field of science that has the potential to revolutionize medicine. The Feinstein Institutes publishes two open-access, international peer-reviewed journals Molecular Medicine and Bioelectronic Medicine. Through the Elmezzi Graduate School of Molecular Medicine, we offer an accelerated PhD program. For more information about how we produce knowledge to cure disease, visit and follow us on LinkedIn.
Yahoo
14-05-2025
- Business
- Yahoo
UTHR Q1 Earnings Call: Double-Digit Growth Continues, Pipeline Expansion Remains Central
Biotechnology company United Therapeutics (NASDAQ:UTHR) reported Q1 CY2025 results exceeding the market's revenue expectations , with sales up 17.2% year on year to $794.4 million. Its non-GAAP profit of $7.28 per share was 11.3% above analysts' consensus estimates. Is now the time to buy UTHR? Find out in our full research report (it's free). Revenue: $794.4 million vs analyst estimates of $752.6 million (17.2% year-on-year growth, 5.6% beat) Adjusted EPS: $7.28 vs analyst estimates of $6.54 (11.3% beat) Adjusted EBITDA: $420.2 million vs analyst estimates of $379 million (52.9% margin, 10.9% beat) Operating Margin: 48.2%, down from 52.6% in the same quarter last year Free Cash Flow Margin: 50.4%, similar to the same quarter last year Market Capitalization: $13.88 billion United Therapeutics reported a first-quarter performance driven by sustained demand for its treprostinil-based therapies, including Tyvaso, Orenitram, and Remodulin. Management attributed the quarter's revenue growth to increased patient referrals and deeper engagement among healthcare providers, particularly within the pulmonary hypertension field. President Michael Benkowitz emphasized, 'We continue to see very strong referrals, starts and patient shipments for all of our treprostinil products.' Looking ahead, United Therapeutics' leadership highlighted a robust late-stage pipeline, ongoing regulatory milestones, and the company's disciplined approach to capital allocation as key factors in its guidance. CEO Dr. Martine Rothblatt outlined expectations for further expansion into new indications and organ transplantation programs, noting, 'We have entered a sustained period of clinical and regulatory events poised to propel our business forward.' Management also reiterated confidence in maintaining double-digit growth, citing upcoming data readouts and planned product launches. Management pointed to broad-based commercial momentum and disciplined investment as the main drivers of first-quarter results, while emphasizing the strategic importance of pipeline development and manufacturing expansion. Treprostinil Product Expansion: Growth was fueled by strong demand for Tyvaso (including both DPI and nebulizer forms), Orenitram, and Remodulin, with a notable increase in both prescriber base and depth of prescribing. Management stated that treprostinil therapies remain central to pulmonary hypertension treatment despite new market entrants. Tyvaso DPI Uptake: Tyvaso DPI (dry powder inhaler) continued gaining share, with new patient starts stabilizing at roughly two-thirds DPI versus one-third nebulizer. Leadership underscored device convenience and dosing flexibility as differentiators supporting sustained uptake. Pricing and Payer Environment: A routine price increase for Tyvaso and Orenitram contributed to revenue, while the impact from Medicare Part D redesign was described as modest and largely offset by manufacturer obligations under the new structure. Pipeline and R&D Progress: Five registration-phase clinical studies are underway, including the TETON trials in idiopathic pulmonary fibrosis and new organ transplantation programs. The company reported positive regulatory feedback on its UTHYMOKIDNEY and UHeart programs, enabling advancement without further animal studies. Manufacturing and Capital Allocation: Ongoing investments include expansion of Tyvaso DPI manufacturing capacity and the commissioning of specialized facilities for organ development. Management highlighted its balanced capital deployment across R&D, corporate development (including the IVIVA and Miromatrix acquisitions), and shareholder returns. Management's outlook for the coming quarters centers on expanding existing product indications, advancing late-stage pipeline programs, and maintaining operational efficiency amid a competitive landscape. Pipeline Readouts and Indications: Upcoming data from the TETON trials in idiopathic pulmonary fibrosis could enable label expansion for Tyvaso, opening access to a larger patient population and driving future revenue. Transplantation Programs: Progress in xenotransplantation, including the planned EXPAND study for genetically engineered kidneys and potential IND filings for UTHYMOKIDNEY and UHeart, may add long-term growth avenues if clinical milestones are met. Competitive and Regulatory Risks: Management acknowledged the increasingly competitive pulmonary arterial hypertension market and evolving payer requirements, but expressed confidence that product differentiation and ongoing R&D investment would preserve growth. Joseph Thome (TD Cowen): Asked about patient selection and learnings from the recent UTHYMOKIDNEY case, including how immunosuppression adjustments informed future trials. Dr. Leigh Peterson explained that future protocols would apply insights from the previous participant, particularly around infection management and immunosuppression. Jessica Fye (JPMorgan): Sought clarity on the revenue impact from the Medicare Part D redesign. President Michael Benkowitz replied that the net benefit this quarter was modest, as additional manufacturer obligations largely offset patient out-of-pocket reductions. Roanna Ruiz (Leerink Partners): Questioned the drivers of Tyvaso DPI growth and any effects from gross-to-net adjustments. Benkowitz indicated that growth was mainly due to patient demand and prescriber adoption, with price changes and gross-to-net impacts minimal in the quarter. Andreas Argyrides (Oppenheimer): Inquired about capital allocation priorities and the potential for further share repurchases or acquisitions. CFO James Edgemond stated that internal R&D, manufacturing, and targeted M&A remain top priorities, with share repurchases considered based on available opportunities. Ash Verma (UBS): Asked about patient volume trends for Tyvaso and competitive positioning versus upcoming products. Benkowitz declined to provide specific patient add figures but noted that revenue trends closely mirror demand, and management remains confident in Tyvaso's market position. In the coming quarters, the StockStory team will be monitoring (1) key clinical milestones such as data readouts from the TETON trials and initial xenotransplantation procedures, (2) the pace of Tyvaso DPI adoption and deeper market penetration, and (3) developments in the competitive pulmonary hypertension landscape. Progress on pipeline programs and the company's ability to navigate regulatory or pricing changes will also be important factors. United Therapeutics currently trades at a forward P/E ratio of 10.5×. Is the company at an inflection point that warrants a buy or sell? See for yourself in our free research report. The market surged in 2024 and reached record highs after Donald Trump's presidential victory in November, but questions about new economic policies are adding much uncertainty for 2025. While the crowd speculates what might happen next, we're homing in on the companies that can succeed regardless of the political or macroeconomic environment. Put yourself in the driver's seat and build a durable portfolio by checking out our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 176% over the last five years. Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Forbes
06-05-2025
- Business
- Forbes
Hydrogen Robinson Helicopter On The Bleeding Edge Of Organ Delivery
Robinson R-44 hydrogen fuel cell powered world's first flight. United Therapeutics Dr. Martine Rothblatt, Chairperson and CEO of United Therapeutics Corporation—a biotechnology company—announced that their Unither Bioelectronics subsidiary successfully completed the world's first lift-off of Proticity, a proof-of-concept hydrogen fuel cell-powered Robinson R44 helicopter, on March 27, 2025, at Roland-Désourdy Airport in Bromont, Québec, Canada. The project's milestones and United Therapeutics's broader aspirations were presented by Dr. Rothblatt at the 4th Annual H2-Aero Symposium, held in early April in Long Beach, California. This article is based on that presentation and a follow-up interview with Mikaël Cardinal, Vice President of Program Management – Organ Delivery Systems and the program's chief engineer. Dr. Rothblatt founded United Therapeutics in 1996 to save the life of her youngest daughter, who was diagnosed with a rare and life-threatening pulmonary condition. Prior to this, she was a pioneer in satellite communications, having founded SiriusXM Radio and played a key role in launching other satellite ventures such as PanAmSat and GeoStar. Under her leadership, United Therapeutics has become a leader in developing treatments for pulmonary arterial hypertension and other life-threatening conditions. The company has also made groundbreaking advances in organ manufacturing and transplantation, including the restoration of otherwise discarded donor lungs. The company is also focused on achieving carbon-neutral production and sustainable delivery of organs. United Therapeutics is actively working toward manufacturing kidneys, hearts, and lungs. One of its three organ manufacturing facilities is already operational, with full capacity expected by 2027, enabling the production of several hundred organs per year at each. United Therapeutics plans to deliver these organs using zero-emissions vertical takeoff and landing aircraft. Dr. Rothblatt herself initiated the development and testing of an electrically powered Robinson helicopter securing a Guinness World Record for the longest flight in 2018. United Therapeutics Proticity team after successful flight testing. United Therapeutics The hydrogen helicopter project is entirely funded by United Therapeutics, with no current government or investor support. Robinson Helicopter Company contributes significant in-kind engineering support, providing time, expertise, and resources. The core team includes a dozen in-house engineers, supplemented by third-party specialists in fuel cell technology. For local development and proof-of-concept flight operations, the team consists of approximately two dozen engineers and several test pilots, working in close collaboration with Robinson's engineering staff. From its electrical helicopter demonstration flights, United Therapeutics gained critical insights into the limitations of battery technology, particularly in delivering sufficient power and range in vertical takeoff and landing operations. To overcome these constraints, the team has turned to hydrogen propulsion, which offers an energy density superior to batteries. The company's long-term goal is to develop a helicopter with a 250-nautical-mile range and a 600-pound payload including the pilot, while near-term goals are set at a 200-nautical-mile range with a 500-pound payload. The company is actively developing a pilot-less variant. Once regulatory clearance is obtained, autonomous features will increase the aircraft's useful payload capacity. In addition to clean air, another key benefit is reduced noise. Without the piston engine of the R44 or the gas turbine of the R66, the electrified version will generate significantly less perceived noise over populated areas. While the company is still quantifying the reduction, early observations show a clear drop in both perceived loudness and psychoacoustic annoyance. Technical parameters of the parallel hybrid fuel cell battery power plant implemented on the ... More helicopter. 178 kW power is demonstrated. United Therapeutics Technical side of the helicopter The developed proof-of-concept powerplant is engineered to match the performance of the original Lycoming IO-540 piston engine it replaces, delivering equivalent continuous power at approximately 2,100 RPM, now via a low-speed electric motor, manufactured by MagniX. The system is computer-controlled to maintain a constant main rotor speed, drawing power from a parallel hybrid setup. During the first flight, the system achieved a peak output of 178 kW, with hover shaft power around 155 kW. The remaining power supported auxiliary systems, such as supply compressors and cooling. The parallel hybrid configuration includes two 92 kW fuel cell stacks and a 45 kW peak-rated booster battery. Over 90% of the time the power during flight came from the fuel cells, with the battery supplementing short bursts of demand—such as rapid torque inputs—ensuring smooth and responsive control. The prototype helicopter features distinctive side pods resembling jet engines, which house a state-of-the-art liquid cooling system. These pods manage the significant heat generated by the fuel cell system through a dedicated cooling loop. While effective for the current design, this solution is not planned for the conforming production model. Instead, upgraded designs will adopt intermediate-temperature fuel cell stacks, which will require significantly smaller cooling systems. Hydrogen on board First flights utilized a Type 4 compressed gas hydrogen tank, featuring a thermoplastic liner wrapped in carbon fiber. Later this year, the company plans to transition to a liquid hydrogen system, using a vacuum-insulated, dual-shell composite tank built by Gloyer-Taylor Laboratories, Inc.. Compared to traditional metallic liquid systems, the composite tanks offer lower thermal mass, significantly reducing hydrogen boil-off. Once released, the cryogenic hydrogen becomes a cold gas, which is then warmed via a heat exchanger before entering the fuel cells. The gaseous system operates at 10,000 psi, storing up to 4.5 kg of hydrogen, while the upcoming liquid system will support up to 20 kg, greatly extending range and endurance. United Therapeutics's R&D test operations are based in Quebec, Canada, where the company benefits from local green liquid hydrogen production via hydroelectric electrolysis, providing essential infrastructure support. To enable on-site refueling, a liquid hydrogen storage tank is being installed at the test facility. The fueling operations will be supplied by tanker trucks from a nearby production plant located just 30 minutes away, ensuring efficient and sustainable fuel logistics. The name Proticity, chosen for the hydrogen-powered helicopter project, refers to the electrochemical process within mitochondria that generates energy for living cells. This biologically inspired concept reflects United Therapeutics' biomedical roots and underscores their leadership mission to merge sustainable innovation with life-saving technologies across both healthcare and aviation.
Yahoo
30-04-2025
- Business
- Yahoo
United Therapeutics (NASDAQ:UTHR) Reports Bullish Q1
Biotechnology company United Therapeutics (NASDAQ:UTHR) reported Q1 CY2025 results topping the market's revenue expectations , with sales up 17.2% year on year to $794.4 million. Its GAAP profit of $6.63 per share was 5.1% above analysts' consensus estimates. Is now the time to buy United Therapeutics? Find out in our full research report. Revenue: $794.4 million vs analyst estimates of $730 million (17.2% year-on-year growth, 8.8% beat) EPS (GAAP): $6.63 vs analyst estimates of $6.31 (5.1% beat) Operating Margin: 48.2%, down from 52.6% in the same quarter last year Market Capitalization: $13.51 billion '2025 is off to a tremendous start as we reported yet another quarter of record revenue,' said Martine Rothblatt, Ph.D., Chairperson and Chief Executive Officer of United Therapeutics. Founded by a mother seeking treatment for her daughter's pulmonary arterial hypertension, United Therapeutics (NASDAQ:UTHR) develops and commercializes medications for chronic lung diseases and other life-threatening conditions, with a focus on pulmonary hypertension treatments. Examining a company's long-term performance can provide clues about its quality. Any business can experience short-term success, but top-performing ones enjoy sustained growth for years. Luckily, United Therapeutics's sales grew at a solid 15.7% compounded annual growth rate over the last five years. Its growth beat the average healthcare company and shows its offerings resonate with customers, a helpful starting point for our analysis. We at StockStory place the most emphasis on long-term growth, but within healthcare, a half-decade historical view may miss recent innovations or disruptive industry trends. United Therapeutics's annualized revenue growth of 22.9% over the last two years is above its five-year trend, suggesting its demand was strong and recently accelerated. This quarter, United Therapeutics reported year-on-year revenue growth of 17.2%, and its $794.4 million of revenue exceeded Wall Street's estimates by 8.8%. Looking ahead, sell-side analysts expect revenue to remain flat over the next 12 months, a deceleration versus the last two years. This projection is underwhelming and implies its products and services will see some demand headwinds. At least the company is tracking well in other measures of financial health. Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. Operating margin is an important measure of profitability as it shows the portion of revenue left after accounting for all core expenses – everything from the cost of goods sold to advertising and wages. It's also useful for comparing profitability across companies with different levels of debt and tax rates because it excludes interest and taxes. United Therapeutics has been a well-oiled machine over the last five years. It demonstrated elite profitability for a healthcare business, boasting an average operating margin of 45.7%. Analyzing the trend in its profitability, United Therapeutics's operating margin rose by 22.8 percentage points over the last five years, as its sales growth gave it immense operating leverage. Zooming into its more recent performance, however, we can see the company's margin has decreased by 2.4 percentage points on a two-year basis. Given its business quality, we're optimistic that United Therapeutics can correct course and return to expansion. In Q1, United Therapeutics generated an operating profit margin of 48.2%, down 4.4 percentage points year on year. This contraction shows it was less efficient because its expenses grew faster than its revenue. Revenue trends explain a company's historical growth, but the long-term change in earnings per share (EPS) points to the profitability of that growth – for example, a company could inflate its sales through excessive spending on advertising and promotions. United Therapeutics's astounding 15.9% annual EPS growth over the last five years aligns with its revenue performance. This tells us its incremental sales were profitable. In Q1, United Therapeutics reported EPS at $6.63, up from $6.17 in the same quarter last year. This print beat analysts' estimates by 5.1%. Over the next 12 months, Wall Street expects United Therapeutics's full-year EPS of $25.06 to grow 9.7%. We were impressed by how significantly United Therapeutics blew past analysts' revenue expectations this quarter. We were also happy its EPS outperformed Wall Street's estimates. Zooming out, we think this was a solid quarter. The stock traded up 2% to $305.90 immediately after reporting. United Therapeutics had an encouraging quarter, but one earnings result doesn't necessarily make the stock a buy. Let's see if this is a good investment. What happened in the latest quarter matters, but not as much as longer-term business quality and valuation, when deciding whether to invest in this stock. We cover that in our actionable full research report which you can read here, it's free. Sign in to access your portfolio
